MX2024014000A - Formas cristalinas de un inhibidor de tyk2 y usos de estas - Google Patents

Formas cristalinas de un inhibidor de tyk2 y usos de estas

Info

Publication number
MX2024014000A
MX2024014000A MX2024014000A MX2024014000A MX2024014000A MX 2024014000 A MX2024014000 A MX 2024014000A MX 2024014000 A MX2024014000 A MX 2024014000A MX 2024014000 A MX2024014000 A MX 2024014000A MX 2024014000 A MX2024014000 A MX 2024014000A
Authority
MX
Mexico
Prior art keywords
crystalline forms
tyk2 inhibitor
tyk2
inhibitor
propanoyl
Prior art date
Application number
MX2024014000A
Other languages
English (en)
Spanish (es)
Inventor
Kolbot By
Travis Remarchuk
Original Assignee
Alumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumis Inc filed Critical Alumis Inc
Publication of MX2024014000A publication Critical patent/MX2024014000A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024014000A 2022-05-13 2024-11-12 Formas cristalinas de un inhibidor de tyk2 y usos de estas MX2024014000A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341528P 2022-05-13 2022-05-13
US202263405577P 2022-09-12 2022-09-12
PCT/US2023/021986 WO2023220338A1 (en) 2022-05-13 2023-05-12 Crystalline forms of a tyk2 inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
MX2024014000A true MX2024014000A (es) 2025-02-10

Family

ID=86760338

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024014000A MX2024014000A (es) 2022-05-13 2024-11-12 Formas cristalinas de un inhibidor de tyk2 y usos de estas

Country Status (11)

Country Link
EP (1) EP4522602A1 (enExample)
JP (1) JP2025516683A (enExample)
KR (1) KR20250009492A (enExample)
CN (1) CN119907791A (enExample)
AU (1) AU2023269081A1 (enExample)
CA (1) CA3253365A1 (enExample)
CL (1) CL2024003456A1 (enExample)
IL (1) IL317011A (enExample)
MX (1) MX2024014000A (enExample)
TW (1) TW202409007A (enExample)
WO (1) WO2023220338A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428571A (zh) * 2022-10-10 2024-07-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
WO2026019902A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250048T1 (hr) * 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba

Also Published As

Publication number Publication date
KR20250009492A (ko) 2025-01-17
JP2025516683A (ja) 2025-05-30
CA3253365A1 (en) 2023-11-16
CL2024003456A1 (es) 2025-04-25
AU2023269081A1 (en) 2024-11-28
CN119907791A (zh) 2025-04-29
TW202409007A (zh) 2024-03-01
WO2023220338A1 (en) 2023-11-16
EP4522602A1 (en) 2025-03-19
IL317011A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
CL2024003456A1 (es) Formas cristalinas de clorhidrato de envudeucitinib, composición farmacéutica, y uso.
RU2458920C2 (ru) Новые соединения
FI3302448T3 (fi) Substituoituja heterosyklyylijohdannaisia cdk-inhibiittoreina
PE20191108A1 (es) Inhibidores selectivos de jak1
PH12022550271A1 (en) Solid forms of an hpk1 inhibitor
AR020065A1 (es) Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende
AR057753A2 (es) Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen
PL4010322T3 (pl) Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie
NO20044866L (no) Pyrazolo-pyrimidin-anilin-forbindelser anvendelige som kinase-inhibitorer
RU2007123675A (ru) Комбинации ингибиторов jak
DE60118430D1 (de) Behandlung gastrointestinaler stroma-tumoren
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
AU2003259521A8 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
DK4039688T3 (da) Substitueret pyrrolopyrimidin og pyrazolopyrimidin som brutons tyrosinkinase- (btk) nedbrydere
MX2022015003A (es) Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
DK3986401T3 (da) Peptidomimetikummet (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4- oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan- 2-yl)-5-guanidinopentanamid til anvendelse i behandlingen af amyotrofisk lateral sklerose
PH12021553202A1 (en) Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide
PL4161929T3 (pl) 1-(5-(2-cyjanopirydyn-4-ylo)oksazolo-2-karbonylo)-4-metyloheksahydropirolo[3,4-b]pirolo-5(1h)-karbonitryl jako inhibitor usp30 do zastosowania w leczeniu dysfunkcji mitochondriów, nowotworu i zwłóknienia
ATE339197T1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten
DE60306546D1 (de) Entzündungshemmende 3-arylthio-3-thiazolylalkylamine
PE20200960A1 (es) Inhibidor de receptor del factor de crecimiento epidermico
EP4326255A4 (en) Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof
CL2023000675A1 (es) [6-[(dietilamino)metil]naftalen-2-il]metil[4-(hidroxicarbamoil)fenil]carbamato de alta pureza
RU2009148049A (ru) Терапевтическое средство для лечения церебрального инфаркта
BR112022018596A2 (pt) Formas cristalinas de um agonista de receptor farnesoide x